Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

• Status: Not yet recruiting
• Trial end date: 2026-07-30
• Target enrollment: 0
• Participant gender: All

Summary

This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of SHR-A1811 in combination with chemotherapy and/or immunotherapy in HER2-positive advanced/metastatic gastric/gastroesophageal junction adenocarcinoma patients.

The Phase II study was designed to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and/or immunotherapy for advanced/metastatic HER2-positive gastric/gastroesophageal conjunctional adenocarcinoma patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Treatments: Capecitabine; Oxaliplatin

Criteria

Inclusion Criteria:

1. Age from 18 to 75 , Male and female participants

2. Local advanced unresectable or metastatic disease Pathologically documented adenocarcinoma of gastric or gastroesophageal junction;

3. HER2 positive;

4. Phase Ib: progression at least one prior Regimen or could not tolerate the standard treatment，pevious anti-HER2 therapy was included Phase II: previously untreated patients ;

5. ECOG 0-1;

6. The expected survival ≥3 months;

7. Sufficient bone marrow and organ functions;

Exclusion Criteria:

1. There were ascites, pleural effusion and pericardial effusion that needed to be treated;

2. Major surgery was performed within 4 weeks;

3. Have active autoimmune disease or history of autoimmune disease;

4. Patients with interstitial pneumonia;

5. There was severe infection within 4 weeks before starting the study treatment;

6. Patients with active pulmonary tuberculosis infection history within 1 year before enrollment;

7. Serious cardiovascular and cerebrovascular diseases;

8. Gastrointestinal perforation and/or gastrointestinal fistula occurred within 6 months before enrollment;